Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective

Pharmacological Research

Volumn 80, Issue , 2014, Pages 36-42

  Bencsik, Péter ^a,c   Pálóczi, János ^a   Kocsis, Gabriella F ^a   Pipis, Judit ^a   Belecz, István ^b   Varga, Zoltán V ^a   Csonka, Csaba ^a,c   Görbe, Anikó ^a,c   Csont, Tamás ^a,c   Ferdinandy, Péter ^c,d  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c PHARMAHUNGARY GROUP   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cardiomyocyte; Coronary occlusion; Ilomastat; In situ zymography; Ischemia reperfusion injury; Matrix metalloproteinase

Indexed keywords

DIMETHYL SULFOXIDE; GELATINASE; GELATINASE A; ILOMASTAT; CARDIOTONIC AGENT; INDOLE DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SIMULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HEART; HEART MUSCLE; MYOCARDIAL INFARCTION; PATHOLOGY; PRIMARY CELL CULTURE; REPERFUSION INJURY;

ANIMALS; CARDIOTONIC AGENTS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GELATINASES; HEART; INDOLES; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; PRIMARY CELL CULTURE; RATS; REPERFUSION INJURY;

EID: 84892565116     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.12.007     Document Type: Article

References (33)

1. P. Ferdinandy, R. Schulz, and G.F. Baxter Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning Pharmacol Rev 59 2007 418 458
2. M. Ovize, G.F. Baxter, F. Di Lisa, P. Ferdinandy, D. Garcia-Dorado, and D.J. Hausenloy et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology Cardiovasc Res 87 2010 406 423
3. P. Bencsik, K. Kupai, Z. Giricz, A. Gorbe, J. Pipis, and Z. Murlasits et al. Role of iNOS and peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats Am J Physiol Heart Circ Physiol 299 2010 512 518
4. P.Y. Cheung, G. Sawicki, M. Wozniak, W. Wang, M.W. Radomski, and R. Schulz Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart Circulation 101 2000 1833 1839 (Pubitemid 30213106)
5. Z. Giricz, M.M. Lalu, C. Csonka, P. Bencsik, R. Schulz, and P. Ferdinandy Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition J Pharmacol Exp Ther 316 2006 154 161 (Pubitemid 41832592)
6. M.M. Lalu, C. Csonka, Z. Giricz, T. Csont, R. Schulz, and P. Ferdinandy Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2 Biochem Biophys Res Commun 296 2002 937 941
7. M.M. Lalu, E. Pasini, C.J. Schulze, M. Ferrari-Vivaldi, G. Ferrari-Vivaldi, and T. Bachetti et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart Eur Heart J 26 2005 27 35 (Pubitemid 40221120)
8. M. Sariahmetoglu, M. Skrzypiec-Spring, N. Youssef, A.L. Jacob-Ferreira, J. Sawicka, and C. Holmes et al. Phosphorylation status of matrix metalloproteinase 2 in myocardial ischaemia-reperfusion injury Heart 98 2012 656 662
9. C.J. Schulze, W. Wang, W.L. Suarez-Pinzon, J. Sawicka, G. Sawicki, and R. Schulz Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury Circulation 107 2003 2487 2492 (Pubitemid 36605233)
10. A.K. Chow, J. Cena, and R. Schulz Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature Br J Pharmacol 152 2007 189 205 (Pubitemid 47517601)
11. R. Schulz Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches Annu Rev Pharmacol Toxicol 47 2007 211 242
12. M.A. Ali, W.J. Cho, B. Hudson, Z. Kassiri, H. Granzier, and R. Schulz Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury Circulation 122 2010 2039 2047
13. G. Dorman, K. Kocsis-Szommer, C. Spadoni, and P. Ferdinandy MMP inhibitors in cardiac diseases: an update Recent Pat Cardiovasc Drug Discov 2 2007 186 194 (Pubitemid 350213804)
14. G. Dorman, S. Cseh, I. Hajdu, L. Barna, D. Konya, and K. Kupai et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility Drugs 70 2010 949 964
15. R.M. Bell, S.P. Kunuthur, C. Hendry, D. Bruce-Hickman, S. Davidson, and D.M. Yellon Matrix metalloproteinase inhibition protects CyPD knockout mice independently of RISK/mPTP signalling: a parallel pathway to protection Basic Res Cardiol 108 2013 0331
16. R.M. Bell, and D.M. Yellon Conditioning the whole heart - not just the cardiomyocyte J Mol Cell Cardiol 53 2012 24 32
17. R.E. Galardy, M.E. Cassabonne, C. Giese, J.H. Gilbert, F. Lapierre, and H. Lopez et al. Low molecular weight inhibitors in corneal ulceration Ann N Y Acad Sci 732 1994 315 323
18. C. Csonka, Z. Szilvassy, F. Fulop, T. Pali, I.E. Blasig, and A. Tosaki et al. Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts Circulation 100 1999 2260 2266
19. C. Csonka, K. Kupai, G.F. Kocsis, G. Novak, V. Fekete, and P. Bencsik et al. Measurement of myocardial infarct size in preclinical studies J Pharmacol Toxicol Methods 61 2010 163 170
20. K. Kupai, G. Szucs, S. Cseh, I. Hajdu, C. Csonka, and T. Csont et al. Matrix metalloproteinase activity assays: importance of zymography J Pharmacol Toxicol Methods 61 2010 205 209
21. L.B. Bugaisky, and R. Zak Differentiation of adult rat cardiac myocytes in cell culture Circ Res 64 1989 493 500 (Pubitemid 19073803)
22. E.A. Woodcock, and S.J. Matkovich Cardiomyocytes structure, function and associated pathologies Int J Biochem Cell Biol 37 2005 1746 1751 (Pubitemid 40961659)
23. T. Csont, A. Gorbe, E. Bereczki, A. Szunyog, E. Aypar, and M.E. Toth et al. Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: role of nitric oxide J Mol Cell Cardiol 48 2010 649 652
24. A. Gorbe, Z. Giricz, A. Szunyog, T. Csont, D.S. Burley, and G.F. Baxter et al. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation Basic Res Cardiol 105 2010 643 650
25. X. Li, F.R. Heinzel, K. Boengler, R. Schulz, and G. Heusch Role of connexin 43 in ischemic preconditioning does not involve intercellular communication through gap junctions J Mol Cell Cardiol 36 2004 161 163 (Pubitemid 38084801)
26. A. Gorbe, Z.V. Varga, J. Paloczi, S. Rungarunlert, N. Klincumhom, and M.K. Pirity et al. Cytoprotection by the NO-donor SNAP against ischemia/reoxygenation injury in mouse embryonic stem cell-derived cardiomyocytes Mol Biotechnol 2013 [Epub. ahead of print]
27. M.M. Castro, A.D. Kandasamy, N. Youssef, and R. Schulz Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases Pharmacol Res 64 2011 551 560
28. J. Fert-Bober, H. Leon, J. Sawicka, R.S. Basran, R.M. Devon, and R. Schulz et al. Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion Basic Res Cardiol 103 2008 431 443
29. S.C. Tyagi, S.G. Kumar, J. Banks, and W. Fortson Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium J Mol Cell Cardiol 27 1995 2177 2189
30. W. Wang, C.J. Schulze, W.L. Suarez-Pinzon, J.R. Dyck, G. Sawicki, and R. Schulz Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury Circulation 106 2002 1543 1549
31. Q.X. Sang, Y. Jin, R.G. Newcomer, S.C. Monroe, X. Fang, and D.R. Hurst et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases Curr Top Med Chem 6 2006 289 316
32. Z.F. Wang, N.P. Wang, S. Harmouche, T. Philip, X.F. Pang, and F. Bai et al. Postconditioning promotes the cardiac repair through balancing collagen degradation and synthesis after myocardial infarction in rats Basic Res Cardiol 108 2013 318
33. A.D. Kandasamy, A.K. Chow, M.A. Ali, and R. Schulz Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix Cardiovasc Res 85 2010 413 423